Last $14.13 USD
Change Today +0.30 / 2.17%
Volume 410.4K
DYAX On Other Exchanges
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

dyax corp (DYAX) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/23/14 - $15.70
52 Week Low
05/1/14 - $6.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DYAX CORP (DYAX)

dyax corp (DYAX) Related Bloomberg News

View More Bloomberg News

dyax corp (DYAX) Related Businessweek News

No Related Businessweek News Found

dyax corp (DYAX) Details

Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and plasma kallikrein-mediated (PKM) angioedemas. The company offers KALBITOR for the treatment of acute attacks of HAE. It is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein, which would be a candidate to prophylactically treat HAE and other PKM disorders. The company distributes KALBITOR through a network of wholesale and specialty pharmacy arrangements. It has agreements with CVie Therapeutics for the development and commercialization of KALBITOR in the treatment of HAE and other angioedema indications in China; and Novellus Biopharma AG for the development and commercialization of KALBITOR for the treatment of HAE and other angioedema indications in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela. The company also has a strategic collaboration agreement with Sigma-Tau Rare Diseases S.A. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other therapeutic indications in Europe, North Africa, the Middle East, and Russia. Dyax Corp. was founded in 1989 and is headquartered in Burlington, Massachusetts.

120 Employees
Last Reported Date: 03/3/14
Founded in 1989

dyax corp (DYAX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $615.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $409.6K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $444.0K
Executive Vice President and General Counsel
Total Annual Compensation: $360.0K
Total Annual Compensation: $148.7K
Compensation as of Fiscal Year 2013.

dyax corp (DYAX) Key Developments

Dyax Mulls Acquisitions

Dyax Corp. (NasdaqGM:DYAX) is seeking acquisitions. Dyax is planning to raise funds from offering and plans to use part of proceeds for acquisitions too. Dyax said, "Except as otherwise provided in the applicable prospectus supplement, we intend to use the net proceeds from the sale of the securities offered by this prospectus for general corporate purposes, which may include working capital, capital expenditures, commercialization and distribution expenditures, manufacturing expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, and the repayment, refinancing, redemption or repurchase of future indebtedness or capital stock."

Dyax Corp. Presents at Boston Biotech NY/NJ CEO Conference, Nov-13-2014 03:45 PM

Dyax Corp. Presents at Boston Biotech NY/NJ CEO Conference, Nov-13-2014 03:45 PM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: George V. Migausky, Chief Financial Officer, Principal Accounting Officer and Executive Vice President.

Dyax Corp. Announces Expansion of Phase 1b Clinical Trial for DX-2930

Dyax Corp. announced the expansion of its ongoing Phase 1b clinical trial evaluating DX-2930 to include additional patients and dosing cohorts. Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein, as a subcutaneous injection for prevention of hereditary angioedema (HAE) attacks. The ongoing Phase 1b clinical trial is a multi-center, randomized, double-blind, placebo-controlled, multiple ascending dose study designed to assess the safety, tolerability and pharmacokinetics of DX-2930 in HAE patients. As of October 31, 2014, 21 subjects were enrolled and completed dosing in three ascending dose cohorts (30 mg, 100 mg and 300 mg) of DX-2930 or placebo. Subjects in each cohort were randomized to active drug or placebo in a 2:1 ratio. Each study subject received two doses of study drug or placebo separated by 14 days and will undergo 15 weeks of follow-up after the second dose. In light of faster than anticipated enrollment rates, Dyax has decided to take the opportunity to further characterize DX-2930 by adding two additional cohorts. Subjects will continue to be randomized to active drug or placebo in a 2:1 ratio and the dosing regimen will remain unchanged. Active drug-treated subjects in the fourth cohort will receive 400 mg of DX-2930. The dose level of the fifth cohort will be decided based upon a review of interim data. Addition of the new dosing cohorts is in accordance with the provisions included in the original protocol which allows enrollment into additional dose groups and/or additional patients at any dose group. Total enrollment can be increased to as many as 36 patients and data from additional patients will be used to expand the DX-2930 safety database and provide potentially informative pharmacodynamic data.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DYAX:US $14.13 USD +0.30

DYAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioCryst Pharmaceuticals Inc $11.83 USD +0.76
Genmab A/S kr354.30 DKK -6.10
MorphoSys AG €76.28 EUR -0.484
Pharming Group NV €0.39 EUR -0.008
XOMA Corp $3.68 USD +0.11
View Industry Companies

Industry Analysis


Industry Average

Valuation DYAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.5x
Price/Book 18.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYAX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at